Skip to content

For Providers

Gain actionable clinical insights with our whole genome platform

Order a Test

Whole Genome Coverage

Standard panel testing looks at less than 0.1% of your genome1.  Our whole genome sequencing platforms provide an extensive analysis of your patient’s genomic makeup, including complex mutations (structural variants, copy number variants, variants in non-coding areas) that are not covered by other panel and exome sequencing tests.

Targeted Panel Sequencing

< 0.1 %

Genome-wide coverage

  • Limited number of point mutations
  • Limited copy number variations
  • Limited structural variations

Whole Exome Sequencing

1 – 2 %

Genome-wide coverage

  • Limited number of point mutations
  • Limited copy number variations
  • Limited structural variations
  • Non-coding areas not covered

Whole Genome Sequencing

> 99 %

Genome-wide coverage

  • More point mutations identified
  • More accurate, genome-wide copy number variations
  • Genome-wide coverage of structural variations
  • Non-coding areas also covered

At Inocras, our goal is to help relieve your diagnostic burden so you can spend more time on what matters most: caring for your patients. Our whole genome platform provides you with additional data, tools, and confidence to support your best medical decision making.

Actionable findings

Our proprietary high-performing bioinformatics algorithm thoroughly analyzes a patient’s genome data and translates it into actionable findings. Our user-friendly report is comprehensive and highlights the findings highly relevant to clinical utility.

Clinical trial matching

We provide detailed clinical trial information matched with each patient’s biomarkers and other pre-screening criteria, saving you time in finding the best matched clinical trials for patients.

Expert support

You’ll have access to our in-house genomic experts (on demand) while our dedicated sales and medical teams are just a phone call away. Your patient will also have access to a genetic counselor session. This counselor is also available to address any questions you may have.

Available Tests

We offer WGS-based diagnostic solutions for cancer and rare diseases.


See your patient’s cancer from new angles. Our whole genome cancer test provides a broader insight compared to many conventional genetic tests.


Cancer profiling diagnostics solution for solid tumor patients. Our test reduces the likelihood of false positives by ruling out benign variants in the tumor sample. It has shown high clinical utility in real-world setting. Nearly 90% of patients had clinical utility using CancerVision2.

  • 2-in-1 test: Paired somatic-germline testing
  • Liquid biopsy for cancer profiling with cfDNA* when tissue sample fails
  • Target-enhanced whole-genome sequencing: An average of 40x depth WGS backbone with focused exploration of an average of over 500x depth for 500 key biomarker genes.
  • All types of alterations: Single nucleotide variants (SNVs), small indel variants, large structural variants (SV) and copy number variants (CNV), including variants in non-coding regions.
  • Genome-wide signatures: Our proprietary algorithms for Tumor Mutational Burden (TMB), Microsatellite instability (MSI), Homologous recombination deficiency (HRD), and more.
  • Germline WGS reports pathogenic germline variants according to ACMG guidelines
  • Expert consultation available upon request (including Molecular Tumor Board)
  • 2-week turnaround time**

* Circulating cell-free DNA (cfDNA)3 refers to extracellular DNA present in body fluid that may be derived from both normal and diseased cells.

** 2 weeks from receipt of the tissue and blood samples at our lab.

Rare Disease

Find clarity in the face of complexity. We combine bioinformatics with in-house clinical expertise to provide timely, accurate, and clinically meaningful insights.



Comprehensive WGS diagnostic solutions for rare diseases. Our internal study shows RareVision detected 23.6% more rare disease cases that other genetic test methods missed (including targeted panel sequencing, whole exome sequencing).

  • An average of~30x depth for whole genome sequencing, tested with more than 3,000 patients (over 6,000 cases including family members).
  • High clinical utility: 30-50% positive diagnosis rate, depending on age group and disease criteria (on par with the best-in-class pipeline in the world).
  • Genes associated with rare diseases from one of the most up-to-date databases4
  • Following ACMG/ClinGen guidelines and standards
  • Expert consultation available upon request
  • 2-week turnaround time*

* 2 weeks from receipt of the blood samples at our lab.

How to Order a Test

Ordering a test is quick and easy. Contact us at to place your order now.


Contact us to place an order. Our sales rep will reach out to you shortly.


Fill out the test requisition form and collect samples using a supplied sample collection kit.


Ship the samples directly to us.


Receive the test results via email and fax.

Test Requirements

Test Name Specimen Paired Normal TAT Locations Offered
CancerVision 10 FFPE from curls or slides, with H&E stained slide for reference 10mL peripheral blood, or previously extracted DNA from a CLIA certified laboratory 10-14 days Global
RareVision Peripheral blood (3-5mL) N/A 10-14 days Global

What Other Providers Are Saying


“I was finally able to understand why my patient with ER+ breast cancer had an atypical response to the endocrine treatment through Inocras’s whole genome sequencing results. It identified not only somatic mutation (RB1), but also germline mutation (gBRCA2) and mutational signatures (WGS-HRD), which were not captured in other tests. Based on the results, I could predict the current treatment (CDK inhibitor) would have poor outcomes and change the treatment plan completely. It was eye-opening to see both somatic and germline mutations as well as all types of mutational signatures. My patient’s treatment journey would have been much easier if she had undergone a whole genome test at the beginning of her treatment journey.”

Dr. Park, Medical Oncologist - Samsung Medical Center

Frequently Asked Questions

If you don’t see your question answered here, please contact us.

How do I order a test?

To order a test, please download and complete the test requisition form and email it to: Our sales representativess will follow up with you shortly.

How are the tests paid for?

Unfortunately, our tests are not currently covered by insurance. Upon ordering, your patient will receive an invoice for which payment will be required directly from the patient’s out-of-pocket expenses.

How will I receive the results?

Inocras test reports can be accessed as soon as results are ready via our digital reporting portal. You can also receive access to results via secure email or request to have results faxed to you.

What if I don’t understand the results?

You’ll have access to our team of in-house medical experts, researchers, and genomic specialists who can explain the results to you and answer any questions.